Olin and Huntsman: SEC Declares S‑4 Effective for Planned Merger

Key highlights
  • SEC declared Olin's Form S‑4 effective on July 13, 2026.
  • Special meetings for Olin shareholders and Huntsman stockholders are scheduled for August 25, 2026; record date July 9, 2026.
  • Completion expected in the first half of 2027, subject to regulatory approvals and shareholder votes.
  • Management projects over $400 million of synergies: >$300M annual cost synergies by end of year three (90% within 24 months) and >$100M raw material benefits beginning 2031.

Registration and shareholder meetings

On July 13, 2026 the SEC declared effective the Form S‑4 filed by Olin in connection with the proposed all‑stock merger of equals to form OlinHuntsman. Olin and Huntsman commenced mailing the definitive joint proxy statement/prospectus on July 13, 2026. Special meetings are scheduled for August 25, 2026 (Olin at 8:00 a.m. CT; Huntsman at 9:00 a.m. CT) and shareholders and stockholders of record as of the close of business on July 9, 2026 are entitled to vote.

Strategic rationale and synergies

The companies say the combined OlinHuntsman will be a vertically integrated chemicals company with expanded chlorine optionality, complementary upstream and downstream capabilities, and an enhanced footprint across the U.S. Gulf Coast, Europe and Asia. Management expects to realise more than $400 million of cost synergies and integration benefits, including over $300 million of annual cost synergies by the end of year three (with more than 90% expected within the first 24 months) and more than $100 million of additional raw material integration benefits beginning in 2031, alongside revenue synergies and margin improvement across end markets.

Timing, approvals and conditions

Completion of the transaction is expected in the first half of 2027 and remains subject to customary closing conditions, required regulatory approvals and approval by both Olin shareholders and Huntsman stockholders.

Forward‑looking statements and risks

The companies note that statements about expected benefits, timing and financial performance are forward‑looking and subject to risks—including failure to obtain approvals, inability to achieve projected synergies, regulatory or market changes, operational and integration risks, financing and indebtedness issues, and other factors described in the SEC filings.

Source: Huntsman